The FY20 Defense Appropriations Act provides funding to the Department of Defense Prostate Cancer Research Program (PCRP) to support innovative, high-impact prostate cancer research. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC).
The FY20 PCRP Program Announcements and General Application Instructions for the following award mechanism is posted on the Grants.gov website.
The mission of the FY20 PCRP is to fund research that will lead to the elimination of death from prostate cancer and enhance the well-being of Service members, Veterans, and all the men and their families who are experiencing the impact of the disease. Within this context, the PCRP is interested in supporting research that addresses specific gaps in prostate cancer research and clinical care, with an emphasis on investing in research that will benefit patients diagnosed with lethal prostate cancer or improve quality of life for men diagnosed with this disease. All applications are required to address one or more of the following FY20 PCRP Overarching Challenges:
- Improve the quality of life for survivors of prostate cancer
- Develop treatments that improve outcomes for men with lethal prostate cancer
Applications must be directly relevant to lethal prostate cancer, which includes patients with metastatic disease; treatment-resistant disease; oligo-metastases; neuroendocrine disease; high-risk localized or locoregional disease, etc.
- Reduce lethal prostate cancer in people of African descent, Veterans, and high-risk or underserved populations
High-risk populations include, but are not limited to, people of African descent (including Caribbean Americans), genetically predisposed populations, Service members, and Veterans. Underserved populations include, but are not limited to, men with limited access to clinical care and resources (in both rural and urban settings), and sexual and/or gender minorities with, or at risk for, prostate cancer.
- Define the biology of lethal prostate cancer to reduce death
Applications must be directly relevant to lethal prostate cancer, which includes patients with metastatic disease; treatment-resistant disease; oligo-metastases; neuroendocrine disease; high-risk localized or locoregional disease; etc. Applications should not focus on topics such as differentiation between low risk and intermediate risk prostate cancer.
Prostate Cancer Pathology Resource Network Award – Letter of Intent due September 10, 2020
Modified for FY20
Independent investigators with a faculty-level appointment (or equivalent) with access to the appropriate facilities
- Provides infrastructure support for the development and maintenance of a prostate cancer biorepository through a collaborative network across multiple institutions that will facilitate the collection, processing, annotation, storage, and distribution of high-quality human prostate cancer biospecimens.
- Each application must include three to five Pathology Resource Sites, one of which will also serve as the Coordinating Center. These organizations will be jointly responsible for developing and maintaining the biorepository for prostate cancer research.
- Major emphasis for biospecimen collection must be placed on the acquisition and distribution of biospecimens in limited supply in the prostate cancer research community.
- In addition to sample collection, the consortium is expected to be a repository for the collection and distribution of molecular data generated from the biospecimens, such as digital images and blood-based germline assessments.
- Each application must include plans for significant accrual from at least one Pathology Resource Site of patient samples from populations that are disproportionately affected (African Americans, African-descent, Veterans, etc.) and underserved (uninsured, rural communities, etc.).
- Sites must provide plans for scalable management operations, quality assurance, bioinformatics and data management, and ethical and regulatory issues.
- Applications should clearly describe benchmarks for utilization of the repository as well as mechanisms for outreach to increase use by the prostate cancer community.
- Maximum funding of $6,000,000 for direct costs (plus indirect costs).
- Maximum period of performance is 3 years.
A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.
For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org. For more information about the PCRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).
Point of Contact:
CDMRP Help Desk